|
Calypso Medical Technologies
Calypso Medical is a medical device company that develops innovative technology to target unmet medical needs in radiation therapy. Its introductory
technology addresses the need for objective motion management through precise and continuous confirmation of a treatment target's location during radiation
therapy.
CircuLite
CircuLite, Inc. is a medical device company founded in November 2004 by Accelerated Technologies, Inc. (ATI) to develop a pocket circulatory assist device for the treatment of NYHA Class III and early Class IV heart failure patients. Paul Spence, MD, a cardiovascular surgeon, conceived the idea of combining a superficially placed miniature blood pump with endovascularly placed inflow and outflow cannulae.
CircuLite’s mission is to change the treatment model of chronic heart failure patients by commercializing a pocket circulatory assist device that can be endovascularly implanted similar to a pacemaker by the interventional cardiologist. A pocket circulatory assist device will allow the transformation of treatment of heart failure from the acute decompensated hospitalized patient to the chronic, ambulatory patient. The CircuLite technology will provide a new treatment option to approximately two million patients who have no other viable option today.
Intarcia
Intarcia is a biopharmaceutical company that applies a targeted approach to the acquisition, development and commercialization of therapeutic products for
use in treating cancer and infectious diseases. Intarcia’s lead programs include a combination therapy for the treatment of hormone dependent breast cancer
in postmenopausal women and an implant to deliver omega interferon for the treatment of hepatitis C.
Kadmus Pharmaceuticals
Kadmus is a biopharmaceutical company that exploits endocannabinoid pathways to develop innovative therapeutics. Endocannabinoids are naturally occurring
signaling molecules whose functions include regulating pain and body weight. Through licensing activity, development partnerships and internal discovery
programs, Kadmus is building a portfolio of compounds with activity against a range of disorders of the central nervous system and metabolic disorders,
including neuropathic pain and obesity.
GeminX Biotechnologies
GeminX specializes in the discovery and development of novel small-molecule cancer therapeutics based on the regulation of apoptosis, the body’s
natural ability to destroy injured or damaged cells. GeminX’s lead product, GX15-070, is a small molecule, pan-inhibitor of Bcl-2 proteins. GeminX
is also developing small molecules that induce apoptosis in p53-defective cancers.
NuGEN Technologies
NuGEN is focused on the development and commercialization of amplification and detection systems for genomic and proteomic research. NuGEN's proprietary
SPIA ™ and Ribo-SPIA ™ amplification and labeling system form the foundation for a wide range of products. The Ovation ™ amplification and labeling system,
the company's first product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis.
Optimer Pharmaceuticals
Optimer is focused on the research and development of anti-infective products to treat serious bacterial infections. Optimer’s core drug discovery
technologies are licensed from Scripps Research Institute and Memorial Sloan-Kettering Cancer Center. The company has a portfolio of pre-clinical and
clinical stage antibiotic compounds. Optimer’s lead product is an antibiotic being developed for the treatment of C. difficile-associated diarrhea (CDAD),
the leading cause of institutional enteric infections.
U-Systems
U-Systems designs, develops, manufactures and markets innovative ultrasound systems and computer-aided detection (CAD) software for medical ultrasound.
The Company’s first product is a Full-Field Breast Ultrasound System™ (FFBU™). The FFBU system automatically scans the whole-breast. It presents the results
to the physician in a mammogram-like format (Somogram™)—enabling high volume, cost-effective ultrasound imaging.
|